AU2017394679A1 - Natural combination hormone replacement formulations and therapies - Google Patents
Natural combination hormone replacement formulations and therapies Download PDFInfo
- Publication number
- AU2017394679A1 AU2017394679A1 AU2017394679A AU2017394679A AU2017394679A1 AU 2017394679 A1 AU2017394679 A1 AU 2017394679A1 AU 2017394679 A AU2017394679 A AU 2017394679A AU 2017394679 A AU2017394679 A AU 2017394679A AU 2017394679 A1 AU2017394679 A1 AU 2017394679A1
- Authority
- AU
- Australia
- Prior art keywords
- estradiol
- progesterone
- subject
- auc
- estrone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430339P | 2016-12-05 | 2016-12-05 | |
| US62/430,339 | 2016-12-05 | ||
| US201762481060P | 2017-04-03 | 2017-04-03 | |
| US62/481,060 | 2017-04-03 | ||
| PCT/US2017/064788 WO2018136161A1 (en) | 2016-12-05 | 2017-12-05 | Natural combination hormone replacement formulations and therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017394679A1 true AU2017394679A1 (en) | 2019-06-13 |
Family
ID=62908279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017394679A Abandoned AU2017394679A1 (en) | 2016-12-05 | 2017-12-05 | Natural combination hormone replacement formulations and therapies |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3548036A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020504093A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200018383A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110290793A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017394679A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019011655A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3045024A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267023A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019006513A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019115913A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018136161A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220105107A1 (en) * | 2020-10-01 | 2022-04-07 | Michael Liguori | Bioidentical progesterone cream infused with nanoemulsified cbd |
| GB202316026D0 (en) * | 2023-10-19 | 2023-12-06 | Theramex Hq Uk Ltd | Methods of prevention or treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US6901278B1 (en) * | 2002-01-29 | 2005-05-31 | Morris Notelovitz | Methods for reducing the risk of breast cancer in and improving the health of women |
| US20040062794A1 (en) * | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
| US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| AR100562A1 (es) * | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
-
2017
- 2017-12-05 MX MX2019006513A patent/MX2019006513A/es unknown
- 2017-12-05 BR BR112019011655A patent/BR112019011655A2/pt not_active IP Right Cessation
- 2017-12-05 AU AU2017394679A patent/AU2017394679A1/en not_active Abandoned
- 2017-12-05 JP JP2019530027A patent/JP2020504093A/ja active Pending
- 2017-12-05 WO PCT/US2017/064788 patent/WO2018136161A1/en not_active Ceased
- 2017-12-05 CN CN201780086119.7A patent/CN110290793A/zh active Pending
- 2017-12-05 CA CA3045024A patent/CA3045024A1/en not_active Abandoned
- 2017-12-05 RU RU2019115913A patent/RU2019115913A/ru not_active Application Discontinuation
-
2018
- 2018-02-02 KR KR1020197019625A patent/KR20200018383A/ko not_active Ceased
- 2018-02-02 EP EP17893482.4A patent/EP3548036A4/en not_active Withdrawn
-
2019
- 2019-06-02 IL IL267023A patent/IL267023A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267023A (en) | 2019-07-31 |
| RU2019115913A (ru) | 2021-01-15 |
| WO2018136161A1 (en) | 2018-07-26 |
| WO2018136161A9 (en) | 2019-08-22 |
| EP3548036A4 (en) | 2020-06-17 |
| RU2019115913A3 (cg-RX-API-DMAC7.html) | 2021-03-19 |
| KR20200018383A (ko) | 2020-02-19 |
| MX2019006513A (es) | 2019-08-14 |
| JP2020504093A (ja) | 2020-02-06 |
| CN110290793A (zh) | 2019-09-27 |
| BR112019011655A2 (pt) | 2019-10-22 |
| EP3548036A1 (en) | 2019-10-09 |
| CA3045024A1 (en) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180221389A1 (en) | Natural combination hormone replacement formulations and therapies | |
| Anawalt et al. | Combined nestorone–testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men | |
| US10806740B2 (en) | Natural combination hormone replacement formulations and therapies | |
| US20190247401A1 (en) | Natural combination hormone replacement formulations and therapies | |
| Murphy et al. | Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding | |
| US11103513B2 (en) | Natural combination hormone replacement formulations and therapies | |
| Duijkers et al. | Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study | |
| US10668082B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US11266661B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US11246875B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| Vogler et al. | Contraceptive Efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1–infected women: pharmacokinetic results of ACTG Trial A5188 | |
| US20190343771A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US20250387408A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| EP3548036A1 (en) | Natural combination hormone replacement formulations and therapies | |
| US20230302015A1 (en) | Natural combination hormone replacement formulations and therapies | |
| CA3007636A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US20250387339A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| Rybacki | HOW SUPPLIED | |
| BR112016009008B1 (pt) | Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol |